Related by context. All words. (Click for frequent words.) 66 EDSS score 66 clinically meaningful improvement 65 nonresponders 64 cEVR 64 Rate ORR 64 ACR# response 63 CDAI score 62 dapagliflozin plus 62 Psoriasis Area 62 bortezomib refractory 62 Expanded Disability Status 62 MADRS score 62 Response Evaluation Criteria 62 ACR# responses 62 Index CDAI 62 Unified Parkinson Disease 62 abdominal pain abdominal discomfort 62 PASI scores 62 methotrexate monotherapy 61 Platelet counts 61 prospectively stratified 61 mg kg dose 61 TLUS 61 RECIST Response Evaluation Criteria 61 tapentadol ER 61 ACR Pedi 61 CIMZIA TM 61 EBMT criteria 61 CSBM 61 evaluable subjects 61 DAS# remission 61 DAS# CRP 61 ACR# [002] 61 DAS# scores 61 lumbar spine BMD 61 UPDRS 61 HAQ DI 60 FOLFOX4 60 ACR# ACR# 60 Crohn Disease Activity 60 HbA 1c levels 60 NYHA functional class 60 placebo p = 60 linaclotide treated 60 postintervention 60 NIH CPSI 60 CIMZIA ™ 60 Non inferiority 60 NIHSS 60 Hepatitis C Antiviral 60 severe exacerbations 60 Non Responders 60 plus dexamethasone 60 EDSS scores 60 annualized relapse 60 morphometric vertebral fractures 60 Solid Tumors criteria 60 IRLS 60 Scale EDSS 60 receiving golimumab 60 binary restenosis 60 achieved CCyR 59 mITT population 59 mcg Albuferon 59 CRp 59 pegylated alpha interferon 59 Flu Cy 59 achieved ACR# 59 certolizumab 59 maximal treadmill 59 KRAS mutations occur 59 CR nPR 59 Hb A1C 59 serum clusterin levels 59 FOLFIRI 59 Brief Psychiatric 59 Free Survival PFS 59 chlorambucil 59 tumor progression TTP 59 seroprotection 59 oxycodone CR 59 Severity Index PASI 59 CANCIDAS 59 mean baseline HbA1c 59 serum HCV RNA 59 APTIVUS r 59 virological response 59 desvenlafaxine succinate 59 serum urate 59 ACTEMRA TM 59 Retreatment 59 tipranavir r 59 IFN α 59 mRS 59 FOLPI 59 QTcF 59 mcg QD 59 remission CR 59 DAS# [002] 59 Montgomery Asberg Depression 59 #mg BID [001] 59 antipsychotic efficacy 59 splenectomized patients 59 CCyR 59 biochemical relapse 59 pegylated interferon alfa 2b 58 glycosylated hemoglobin HbA1c 58 definite stent thrombosis 58 ug kg 58 microbiological eradication 58 Pharmacokinetic parameters 58 clinically meaningful improvements 58 salmeterol fluticasone 58 FFNS 58 follicular lymphomas 58 SGRQ 58 mcg mL 58 8mg/kg 58 prior relapsers 58 mg/m2 dose 58 % CI #.#-#.# [007] 58 4mg/kg 58 % Confidence Interval 58 mg BID dose 58 #mg/day [001] 58 lopinavir r arm 58 nodular partial response 58 hours postdose 58 null responders 58 % CI #.#-#.# [003] 58 log# reduction 58 virologic response 58 nondiabetic patients 58 concomitant medications 58 relapsers 58 pharmacodynamic PD 58 atazanavir ritonavir 58 6MWD 58 CDAI 58 HbA 1c 58 receiving highly emetogenic 58 clinical meaningfulness 58 Scale EDSS score 58 p = NS 58 HBeAg negative patients 58 mcg linaclotide 58 mL/min/#.# m 2 58 comparator arm 58 radiographic progression 58 undetectable HBV DNA 58 octreotide LAR 58 serologically active patients 58 prospectively defined 58 Secondary endpoints 58 Virologic 57 Randomized Evaluation 57 Primary endpoints 57 VELCADE melphalan 57 mcg BID 57 XIENCE V PROMUS Stent 57 PSA nadir 57 anemia hemoglobin 57 Thrombolysis 57 gemcitabine carboplatin 57 secondary efficacy endpoint 57 complete cytogenetic response 57 ADAS cog 57 Engerix B 57 ARB telmisartan 57 bronchial hyperresponsiveness 57 lacosamide 57 icatibant 57 IRLS score 57 adalimumab 57 Doxil ® 57 RECIST criteria 57 Platinol ® 57 corticosteroid dose 57 ALT flares 57 HDRS 57 adefovir treated 57 TPV r 57 plus prednisone 57 migalastat HCl 57 progression TTP 57 Score TOS 57 transaminases 57 MMSE score 57 dosing cohort 57 REYATAZ r arm 57 mg BID 57 Operative mortality 57 TEAEs 57 aminotransferases 57 Solid Tumors 57 haematologic 57 Rating Scale MADRS 57 DOXIL 57 oral FTY# 57 statistical significance p 57 ETDRS 57 cytogenetic response 57 PSADT 57 Health Assessment Questionnaire 57 antibody titer 57 viral kinetics 57 p = #.# [003] 57 moderate renal impairment 57 Dyspnea 57 relapsed MM 57 HCV Genotype 57 docetaxel prednisone 57 MabCampath 57 Kaplan Meier analysis 57 Ejection Fraction 57 diameter stenosis 57 EDSS 56 pCR 56 plus MTX 56 achieved statistical significance 56 GOUT 56 R# #mg BID 56 fluticasone salmeterol 56 LEXIVA r 56 HAM D# scores 56 lispro 56 glomerular filtration 56 albumin excretion rate 56 complete Early Virological 56 Kaplan Meier method 56 Relapsing Multiple Sclerosis 56 Folfox 56 tenecteplase 56 oral allopurinol 56 SUVmax 56 unfractionated heparin UFH 56 plasma HCV RNA 56 FluCAM 56 NLX P# 56 periprocedural 56 fasting plasma glucose FPG 56 pegylated interferon alpha 56 Median PFS 56 mg ustekinumab 56 Monotherapy 56 statistically significant p = 56 spirometric 56 Key secondary endpoints 56 Elitek 56 lymphocytosis 56 plus methotrexate 56 #mg BID [002] 56 mg Proellex 56 CIMZIA TM certolizumab pegol 56 CR CRu 56 μmol L 56 RGT arm 56 Rating Scale UPDRS 56 ACUITY trial 56 PCWP 56 5-FU/LV 56 AST ALT 56 Secondary endpoints include 56 divalproex sodium 56 QTc prolongation 56 ARCALYST ® 56 mCi kg 56 paraprotein 56 achieved sustained virological 56 Kaplan Meier survival 56 ADCS CGIC 56 salmeterol fluticasone propionate 56 NNT = 56 ULORIC 56 invasive aspergillosis 56 -#.# log# 56 peginterferon alfa 2a 56 timepoint 56 highly emetogenic 56 locoregional disease 56 solifenacin 56 EURIDIS 56 μg kg 56 Target Lesion Revascularization TLR 56 tacrolimus ointment 56 coronary stenosis 56 evaluable 56 HBeAg positive patients 56 noninferiority 56 tipranavir ritonavir 56 peak VO2 56 μg dose 56 Autologous Stem Cell Transplantation 56 sensitivity specificity 56 alicaforsen enema 56 PegIFN RBV 56 Castration Resistant Prostate Cancer 56 ALT elevations 56 -#.# log# copies mL 56 adjunctive ABILIFY 56 IFN beta 56 patients evaluable 56 urinary N telopeptide 56 nicardipine 56 BARACLUDE ® 56 ABC/3TC 56 apnea hypopnea index 56 microbiologically evaluable 56 baseline FEV 56 PREZISTA r 56 alteplase 56 pT3 56 neostigmine 56 ARIXTRA 55 Partial Response 55 mg TID 55 vincristine doxorubicin 55 endoscopic remission 55 HOMA IR 55 atheroma volume 55 mucosal healing 55 virologic failure 55 efficacy endpoint 55 CsA 55 resected pancreatic cancer 55 BENICAR HCT 55 urate lowering therapy 55 CPAP adherence 55 complete cytogenetic 55 standard chemotherapy regimen 55 WOMAC pain 55 PEG IFN 55 sUA 55 sub maximal 55 MCyR 55 baseline A1C 55 neutrophil counts 55 serum aminotransferase levels 55 placebo dexamethasone 55 p ≤ 55 tolvaptan 55 pain palliation 55 Percutaneous Coronary Intervention 55 alanine aminotransferase ALT 55 Y BOCS 55 timepoints 55 venlafaxine XR 55 oral corticosteroids 55 multivariate Cox 55 prespecified 55 rizatriptan 55 Relapsing Remitting Multiple Sclerosis 55 NIHSS score 55 TNF antagonist 55 Treated Patients 55 confirmed CCyR 55 adenoma recurrence 55 serum HBV DNA 55 HbA1C levels 55 insulin detemir 55 azacytidine 55 events AEs 55 preintervention 55 ertapenem 55 STRIDE PD 55 achieved PASI 55 leukocyte count 55 HBeAg seroconversion 55 mcg albinterferon alfa 2b 55 Stent Restenosis 55 secondary endpoint 55 FDA defined valvulopathy 55 demonstrated clinically meaningful 55 XELOX 55 Visual Analogue Scale VAS 55 Pharmacokinetic 55 posttreatment 55 Solid Tumors RECIST 55 methacholine challenge 55 intraobserver 55 serum concentrations 55 Pharmacodynamic 55 ADAGIO study 55 primary patency 55 univariate 55 Severity MSCS score 55 rosuvastatin #mg 55 pulmonary exacerbation 55 serum phosphorus 55 Traficet EN 55 creatinine ratio 55 eplerenone 55 postdose 55 certolizumab pegol 55 interquartile range IQR 55 elevated ALT 55 Ishak fibrosis score 55 lowest tertile 55 arterial thromboembolic events 55 myocardial necrosis 55 NATRECOR R 55 sensory neuropathy 55 composite endpoint 55 Cholinesterase Inhibitors 55 free survival PFS 55 active comparator 55 plasma uric acid 55 Natalizumab 55 virological failure 55 pulmonary exacerbations 55 laboratory abnormalities 55 Alzheimer Disease Assessment 55 Virologic failure 55 somatostatin analog 55 LVEF 55 mg QD 55 QTc 55 flow mediated dilation 55 mCRC patients 55 ng dl 55 neurologic progression 55 ropivacaine 55 symptomatic VTE 55 MAS XR 55 baminercept 55 Montgomery Åsberg Depression 55 teriflunomide 55 infarct size 55 baseline HbA1c 55 pharmacodynamic parameters 55 INVEGA ® 55 ATV RTV 55 CorVue ™ 55 median PFS 55 plasma cortisol 55 DLTs 55 amoxicillin clavulanate 55 serum cortisol 55 #mg dose [002] 55 etanercept 55 ribavirin RBV 55 postprocedure 55 Solid Tumours 55 paricalcitol 55 elevated LDH 55 mL/min/#.# m2 55 melphalan prednisone 54 sipuleucel T 54 QRS duration 54 biochemical recurrence 54 AUC0 54 Teriflunomide 54 hemoglobin A1c HbA1c 54 colorectal adenoma 54 Secondary endpoints included 54 androgen suppression 54 EMBLEM ™ 54 Negative Symptoms 54 NIS LL 54 mean baseline A1C 54 UPDRS Part III 54 sustained virologic response 54 xanthine oxidase inhibitor 54 relapsing multiple sclerosis 54 sustained virological response 54 eosinophilic asthma 54 GAMMAGARD 54 hematologic toxicity 54 Histologic 54 GG genotype 54 Peg IFN 54 TIMP 1 54 aspartate aminotransferase AST 54 statistically significant improvement 54 docetaxel pretreated 54 glycated hemoglobin levels 54 pretreatment serum 54 #mg BID [003] 54 Metastatic Prostate Cancer 54 poststroke 54 #mg QD [002] 54 Kaplan Meier estimate 54 disease progression TTP 54 VaD 54 Global Impression CGI 54 secondary efficacy endpoints 54 prucalopride 54 Desvenlafaxine Succinate 54 SVR# 54 mTSS 54 ng dL 54 fibrinolysis 54 Zentase 54 YMRS 54 creatinine clearance 54 odds ratios ORs 54 Baseline characteristics 54 neutropaenia 54 metabolic parameters 54 lispro alone 54 IOP lowering 54 x ULN 54 virologic responses 54 mg q#h 54 SSRI citalopram 54 prespecified secondary 54 evaluable patients 54 oral diclofenac 54 ST Elevation Myocardial 54 efavirenz EFV 54 intravenous diuretics 54 WOMAC 54 PREZISTA r arm 54 recurrent venous thromboembolism 54 Ramipril 54 peginterferon alfa 2a #KD 54 sirolimus eluting stents 54 pramipexole 54 hypophosphatemia 54 Subgroup analysis 54 Fibromyalgia Impact Questionnaire 54 urinary albumin 54 QD dosing 54 virologic response EVR 54 Apidra ® 54 p = .# [002] 54 mg kg hr 54 doxorubicin docetaxel 54 serum phosphorous 54 HbA1c levels 54 FOLFIRI alone 54 baseline LDH 54 mg dose 54 FluCAM arm 54 rimonabant #mg/day 54 SSRI SNRI 54 ejection fractions 54 Decitabine 54 subscore 54 zonisamide SR 54 intermittent dosing 54 #mg/day [002] 54 Amrubicin 54 multivariable adjusted 54 Severe Asthma 54 placebo fluoxetine 54 crizotinib PF # 54 Pemetrexed 54 spontaneous bowel movements 54 OGTT 54 DAPT 54 lopinavir r 54 systolic BP 54 attain statistical significance 54 bivalirudin monotherapy 54 response CCyR 54 ADAS Cog 54 log# copies mL 54 idraparinux 54 hematologic parameters 54 blood Phe 54 Tumor Response 54 Capacity FVC 54 statistically significant p 54 Postoperative 54 GLIADEL R Wafer 54 tocilizumab 54 Hb A1c 54 iPTH 54 titrated glipizide 54 Score DAS 54 elevated troponin 54 argatroban 54 RoACTEMRA 54 CrCl 54 recurrent glioblastoma multiforme 54 CC genotype 54 oral Hycamtin 54 plus ribavirin 54 Negative Syndrome 54 chemoradiotherapy 54 Study Evaluating 54 metastatic CRC 54 chemoradiation therapy 54 foveal thickness 54 estimated GFR 54 ALSFRS R 54 BPH Symptom Score 54 adalimumab Humira 54 follicular lymphoma FL 54 ALT elevation 54 GSK# [001] 54 SIMPADICO 54 symptom exacerbation 54 dose cohort 54 A1c levels 54 elevated transaminases 54 TNSS 54 APTIVUS 54 ZOLINZA 54 serum ALT 54 IU ml 54 treatment emergent AEs 53 low dose Iluvien 53 titration phase 53 aldosterone antagonist 53 ALT AST 53 monophasic 53 -#.# mg dL [002] 53 Cmax 53 confidence intervals CIs 53 nonsignificant trend 53 diuretic chlorthalidone 53 BENICAR 53 TRANSFORMS 53 Hepatotoxicity 53 rFVIIa 53 glatiramer acetate 53 placebo p 53 abacavir Ziagen 53 preoperative PSA 53 ibandronate 53 tirofiban 53 pg ml 53 adjunctive placebo 53 HER2 expression 53 Kaplan Meier curves 53 quetiapine 53 μg L 53 urine albumin 53 confidence interval CI 53 Kaplan Meier estimates 53 RE LY ® 53 β blockers 53 antithrombotic therapy 53 nonsignificant 53 lactate dehydrogenase LDH 53 Pegasys ® 53 racemic albuterol 53 log# IU mL 53 BRIM2 53 Score DAS# 53 leucopenia 53 Fulvestrant 53 Kaplan Meier 53 WOMAC scores 53 arterial oxygen saturation 53 echocardiographic parameters 53 hepatocellular carcinomas 53 stage IIIb IV 53 opioid induced bowel dysfunction 53 MGd 53 emetic episodes 53 Symptom Score 53 probable stent thrombosis 53 irbesartan 53 IBDQ 53 statistically nonsignificant 53 Ranolazine 53 plus gemcitabine 53 generalized edema 53 mesalamine granules 53 serum phosphate levels 53 + PH# 53 Index CDAI score 53 dyspnoea 53 Betaferon ® 53 antithymocyte globulin 53 antiretroviral naive 53 #.#mg/dL 53 univariate analysis 53 TMC# r 53 #.#/#.# mmHg [001] 53 NYHA 53 Secondary efficacy endpoints 53 nasal symptom 53 prodromal symptoms 53 death reinfarction 53 receiving Vectibix monotherapy 53 Long Term Efficacy 53 alemtuzumab treated 53 azacitidine 53 interquartile range 53 rapid virological response 53 p = .# [001] 53 RESIST studies 53 treatment naive genotype 53 Tiotropium 53 mg kg belimumab 53 budesonide pMDI 53 low dose dexamethasone 53 galiximab 53 brivaracetam 53 bosentan 53 fosbretabulin 53 squamous histology 53 efficacy evaluable 53 Placebo Controlled Trial 53 MMSE scores 53 Active Ulcerative Colitis 53 azilsartan medoxomil 53 ASIA Impairment 53 surrogate endpoint 53 myocardial reperfusion 53 ritonavir boosted 53 hemoglobin A1c levels 53 Serum creatinine 53 hepatic enzyme 53 hepatic enzymes 53 sinus rhythm 53 normotensive 53 underwent surgical resection 53 intravenous dosing 53 locoregional 53 low dose cytarabine 53 HAMD 53 mRCC 53 Fasting plasma glucose 53 % CI #.#-#.# [006] 53 ARCOXIA 53 gout flares 53 posaconazole 53 preoperative chemotherapy 53 PANSS 53 Functional Outcomes 53 FOLFIRINOX 53 UACR 53 REYATAZ ® 53 hip BMD 53 partial remissions 53 COPD exacerbation 53 Bevacizumab 53 achieving PASI 53 sirolimus stent 53 infliximab 53 Disease Activity 53 RECIST 53 Randomized Double Blind 53 mcg kg 53 Fludara 53 NPH insulin 53 Skin sterol 53 metastatic RCC 53 stage IIIB 53 Metastatic Renal Cell Carcinoma 53 receiving VICTRELIS 53 CNS LS 53 μg liter 53 EDEMA3 53 SELENA SLEDAI score 53 mitoxantrone plus 53 Scale PANSS 53 Oral Fingolimod 53 mg kg Hematide 53 peg interferon 53 rapid virologic response 53 tiotropium 53 intermittent claudication 53 KRAS status 53 Pharmacokinetics PK 53 MCID 53 CI #.#-#.# [001] 53 KRAS wild 53 mitoxantrone 53 nonrandomized 53 ADCS ADL 53 ug dose 53 Adjuvant Therapy 53 mmHg diastolic 53 sirolimus eluting stent 53 Rating Scale BPRS 53 idiopathic PD 53 diastolic BP 53 serum testosterone 53 EQUETRO 53 calculated creatinine clearance 53 VcMP 53 Partial Responses 53 highest tertile 53 Symptom severity 53 FDG-PET/CT 53 Thal Dex 53 fondaparinux 53 isoproterenol 53 T2DM 53 Brief Pain 53 lumbar spine bone 53 Lucentis monotherapy 53 HRQoL 53 Hamilton Anxiety Scale 53 nucleoside naive patients 53 liver histology 53 Abbott HUMIRA 53 nausea photophobia 53 FACIT Fatigue 53 Complete Remission 53 nonobese 53 plus medroxyprogesterone acetate 53 transcranial Doppler ultrasound 53 Adalimumab 53 pg mL 53 Prolongs Survival 53 Plasma concentrations 53 fluorouracil 52 PsA 52 aspartate aminotransferase 52 NYHA class 52 cTnI 52 moderate hepatic impairment 52 MACCE 52 Percutaneous Tibial Nerve Stimulation 52 recurrent VTE 52 oblimersen 52 neoadjuvant chemotherapy 52 TNF antagonists 52 RAPAFLO R 52 DMARD 52 peginterferon 52 Visual acuity 52 Neuropsychiatric Inventory NPI 52 INCB# [003] 52 cisplatin vinorelbine 52 COPERNICUS 52 statistical significance p = 52 uM 52 detectable HCV RNA 52 MoxDuo TM IR 52 advanced adenomas 52 euthymic 52 Bosentan 52 expiratory flow 52 non menstrual pelvic 52 Welchol 52 pharmacokinetic parameters 52 ximelagatran 52 baseline serum creatinine 52 isolated systolic hypertension 52 eNO 52 caspofungin 52 Global Impression 52 inotropic 52 dobutamine 52 splenectomized 52 autonomic dysfunction 52 % CI #.#-#.# [001] 52 pericardial effusion 52 mg qd 52 abacavir lamivudine 52 diabetic gastroparesis 52 lymphocyte counts 52 undetectable HCV RNA 52 CTEPH 52 F FDG PET 52 methotrexate therapy 52 experienced virologic failure 52 Lupuzor ™ 52 infliximab monotherapy 52 mild renal insufficiency 52 #mg doses [002] 52 BARACLUDE r 52 VerifyNow P#Y# Test 52 macroalbuminuria 52 PANSS scores 52 Improves Outcomes 52 plasma leptin 52 fibrinolytic therapy 52 briakinumab 52 ONGLYZA saxagliptin 52 oxycodone IR 52 histologically confirmed 52 CK MB 52 Common Toxicity Criteria 52 FOLFOX 52 AUA Symptom Score 52 P = .# 52 sustained ventricular tachycardia 52 tumor shrinkage 52 pT2 52 COZAAR 52 achieve sustained virologic 52 analgesic efficacy 52 TYGACIL 52 adriamycin 52 residual platelet reactivity 52 CLL SLL 52 nausea somnolence 52 dosage regimens 52 ADHD RS 52 specific antigen PSA 52 MMSE 52 Glycemic Control 52 unresectable HCC 52 LPV r 52 glycosylated hemoglobin 52 gastric pH 52 subscale scores 52 febuxostat 52 SCr 52 receiving ISENTRESS 52 nerve conduction velocity 52 TNF inhibitor 52 retrospective observational study 52 EGFR TKI 52 Phase 2b Study 52 liposome injection 52 mg clopidogrel 52 UPDRS motor 52 tumor histology 52 serum phosphate 52 hepatic insulin sensitivity 52 IIIa inhibitor 52 VAPRISOL 52 transdermal estradiol 52 antiretroviral naïve 52 cinacalcet 52 Meets Primary Endpoint 52 IIIa inhibitors 52 undetectable viral 52 Hormone Receptor Positive 52 Neuropsychiatric Inventory 52 OAB symptoms 52 mycophenolate mofetil 52 aminotransferase levels 52 EQ 5D 52 Interrater reliability 52 events TEAEs 52 achieved sustained virologic 52 transaminase levels 52 ST Segment Elevation 52 rotigotine 52 infusional 5-FU/LV 52 dose proportionality 52 Lower Limb 52 HGPIN 52 HBeAg 52 VADT 52 ZACTIMA 52 doripenem 52 Pioglitazone 52 Hypotension 52 undetectable virus HCV 52 dose cytarabine 52 Logistic regression 52 gadobutrol 52 HBV DNA 52 posttest 52 Renal Function 52 Stenting Trial 52 conditional logistic regression 52 severe neutropenia 52 linear regression analyzes 52 underwent resection 52 nonmetastatic prostate cancer 52 Events MACE 52 pegylated interferon alfa 52 ziprasidone 52 NMIBC 52 periprocedural MI 52 Statistically Significant 52 biphasic 52 Hormone Refractory Prostate Cancer 52 #.#,#.# [001] 52 dalteparin 52 hsCRP levels 52 colesevelam HCl 52 concurrent chemoradiation 52 juvenile idiopathic arthritis 52 epoetin alpha 52 electrophysiologic 52 dosing cohorts 52 pulmonary artery pressure 52 CIBIC plus 52 receiving APTIVUS r 52 LIALDA 52 fingolimod 52 serum calcium levels 52 NATRECOR ® 52 p = #.# [002] 52 CHOP chemotherapy 52 Follicular Lymphoma 52 refractory AML 52 Ozarelix 52 Scale cognitive subscale 52 UPDRS scores 52 piperacillin tazobactam 52 prednisone prednisolone plus 52 -#.# mg dL [001] 52 extrapyramidal symptoms 52 umol L 52 trials RCTs 52 HbA 1C 52 RAPTIVA 52 femoral neck BMD 52 systolic dysfunction 52 LV ejection fraction 52 Zyclara 52 FOLFOX6 52 clodronate 52 ADHD Rating Scale